MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of...
MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of...
MBX生物科學宣佈完成了MBX 1416的單劑量和多劑量遞增的1期試驗中最後一個受試者的最後一次訪問，該公司正在開發該藥物用於治療...
MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of Post-Bariatric Hypoglycemia
MBX生物科學公司宣佈，MBX 1416的1期單劑量和多劑量遞增試驗中最後一名受試者的最後一次訪視已完成，該藥物是公司正在開發用於治療減重手術後低血糖的長效胰高血糖素樣肽1受體拮抗劑。
MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of the last subject's last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the Company's long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist in development for the treatment of post-bariatric hypoglycemia (PBH).
MBX生物科學公司（納斯達克：MBX）是一家專注於發現和開發新型精確肽療法以治療內分泌和代謝疾病的臨床階段生物製藥公司，今天宣佈其MBX 1416的1期單劑量和多劑量遞增試驗中最後一名受試者的最後一次訪視已完成，該藥物是公司正在開發用於治療減重手術後低血糖（PBH）的長效胰高血糖素樣肽1（GLP-1）受體拮抗劑。
資訊熱榜
更新時間